Abstract | BACKGROUND AND OBJECTIVES: DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Subjects who completed TEMPO 4:4, REPRISE, or other tolvaptan trials could enroll in this prospective, multinational, open-label safety study. Assessments included monthly liver enzyme testing during the first 18 months of tolvaptan exposure and every 3 months thereafter. RESULTS: Among 1803 subjects, median tolvaptan exposure during the extension was 651 days (interquartile range, 538-924), and cumulative exposure (extension and previous trials) was ≤11 years. Subjects entering from REPRISE placebo experienced more aquaretic adverse events compared with subjects from TEMPO 4:4 or REPRISE tolvaptan (i.e., patients with prior long-term tolvaptan exposure). Liver enzyme elevations also occurred more frequently in subjects from REPRISE placebo. Percentages experiencing ALT ≥3/≥5/ ≥10/≥20 times the upper limit of normal were 3.2%/2.1%/0.9%/0.7%, respectively, in subjects from REPRISE placebo and 0.6%-1.1%/0.0%-0.1%/0%/0%, respectively, in those from REPRISE tolvaptan and TEMPO 4:4. Percentages experiencing AST ≥3/ ≥5/≥10/≥20 times the upper limit of normal were 6.9%/3.8%/2.3%/0.8%, respectively, in subjects from REPRISE placebo and 0.9%-2.0%/0.0%-1.0%/0%/0%, respectively, in those from REPRISE tolvaptan and TEMPO 4:4. No Hy Law cases occurred. CONCLUSIONS: No new safety signals emerged during this long-term extension. Monthly liver function testing for the first 18 months of treatment appeared to enable effective detection and management of transaminase elevations. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Open Label Extension of TEMPO 3:4, NCT02251275.
|
Authors | Vicente E Torres, Arlene B Chapman, Olivier Devuyst, Ron T Gansevoort, Ronald D Perrone, Jennifer Lee, Molly E Hoke, Alvin Estilo, Olga Sergeyeva |
Journal | Clinical journal of the American Society of Nephrology : CJASN
(Clin J Am Soc Nephrol)
Vol. 16
Issue 1
Pg. 48-58
(12 31 2020)
ISSN: 1555-905X [Electronic] United States |
PMID | 33376102
(Publication Type: Clinical Trial, Phase III, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2021 by the American Society of Nephrology. |
Chemical References |
- Antidiuretic Hormone Receptor Antagonists
- Tolvaptan
- Aspartate Aminotransferases
- Alanine Transaminase
|
Topics |
- Adult
- Alanine Transaminase
(blood)
- Antidiuretic Hormone Receptor Antagonists
(adverse effects)
- Aspartate Aminotransferases
(blood)
- Chemical and Drug Induced Liver Injury
(blood, etiology)
- Female
- Humans
- Male
- Middle Aged
- Polycystic Kidney, Autosomal Dominant
(drug therapy)
- Prospective Studies
- Time Factors
- Tolvaptan
(adverse effects)
|